Biomarkers for AAA: Encouraging steps but clinical relevance still to be delivered

Authors

  • Nay Min Htun,

    1. Baker IDI Heart and Diabetes Institute, Melbourne, Australia
    2. Monash University, Melbourne, Australia
    3. The Alfred Hospital, Melbourne, Australia
    Search for more papers by this author
  • Karlheinz Peter

    Corresponding author
    1. Baker IDI Heart and Diabetes Institute, Melbourne, Australia
    2. Monash University, Melbourne, Australia
    3. The Alfred Hospital, Melbourne, Australia
    • Correspondence: Professor Karlheinz Peter, Baker IDI Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC 3004, Australia

      E-mail: karlheinz.peter@bakeridi.edu.au

    Search for more papers by this author

Abstract

Potential biomarkers have been investigated using proteomic studies in a variety of diseases. Some biomarkers have central roles in both diagnosis and monitoring of various disorders in clinical medicine, such as troponins, brain natriuretic peptide, and C-reactive protein. Although several biomarkers have been suggested in human abdominal aortic aneurysm (AAA), reliable markers have been lacking. In this issue, Moxon et al. [Proteomics Clin Appl. 2014, 8, 762-772] undertook a broad and systematic proteomic approach toward identification of biomarkers in a commonly used AAA mouse model (AAA created by angiotensin-II infusion). In this mouse model, apolipoprotein C1 and matrix metalloproteinase-9 were identified as novel biomarkers of stable AAA. This finding represents an important step forward, toward a clinically relevant role of biomarkers in AAA. This also encourages for further studies toward the identification of biomarkers (or their combinations) that can predict AAA progression and rupture, which would represent a major progress in AAA management and would establish an AAA biomarker as a much anticipated clinical tool.

Ancillary